Skip to main content

Michaela Ann Dinan

Adjunct Associate Professor in Population Health Sciences
Population Health Sciences
Duke Box 104023, Durham, NC 27710
60 College St, PO Box 208034, New Haven, CT 06520

Overview


Dr. Dinan is a health services researcher by training and she specializes in using econometric and epidemiologic methodologies to analyze complex datasets. Specifically, Dr. Dinan's research involves issues related to advances in cancer care technologies, such as emerging treatments and diagnostics, and how these advances in technologies impact different cancer outcomes and experiences such as access, quality of care, cost of care, and health disparities.

Dr. Dinan has led studies funded by the National Institutes of Health, the American Cancer Society, and the Agency for Healthcare Research and Quality. She is currently leading an NCI-funded R01 study examining multi-level factors that contribute to disparities in access and adherence to oral anticancer agents for patients with kidney cancer. Dr. Dinan is also leading a study funded by the ACS to develop and validate risk prediction algorithms to inform efficient and high-quality care for long-term cancer survivors.

Areas of expertise: Health Economics, Health Policy, and Health Services Research

Current Appointments & Affiliations


Adjunct Associate Professor in Population Health Sciences · 2023 - Present Population Health Sciences, Basic Science Departments

In the News


Published August 27, 2015
Breast Cancer Risk Score Impacts Use of Chemotherapy

View All News

Recent Publications


Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer.

Journal Article J Natl Cancer Inst · January 1, 2026 BACKGROUND: Cardiovascular disease (CVD) is the leading cause of noncancer mortality in long-term cancer survivors. Population-level assessment of cancer-related exposures is limited with respect to long-term cardiovascular risk in older survivors who have ... Full text Link to item Cite

Personalized risk assessment of frailty in long-term cancer survivors.

Journal Article J Geriatr Oncol · January 2026 INTRODUCTION: Due to the growth of the cancer survivor population, strategies to facilitate efficient delivery of survivorship care are critical to reduce the risk of adverse events associated with frailty. The objective of this study was to develop a risk ... Full text Link to item Cite

Treatment exposure-based risk-stratification for care of survivors of childhood cancer: a report from the childhood cancer survivor study.

Conference J Natl Cancer Inst · December 1, 2025 BACKGROUND: Treatment exposure-based risk-stratification of long-term cancer survivors may help inform health care in survivorship clinics. We used the large, diverse population of the Childhood Cancer Survivor Study to test a modified, exposure-based stra ... Full text Link to item Cite
View All Publications

Recent Grants


Disparities in the Use of Oral Anticancer Agents in Kidney Cancer

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2020

Bladder Cancer in Older Adults - Treatment and Outcomes

ResearchCo Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2016 - 2017

View All Grants

Education


University of Virginia · 2003 B.S.